Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer-Reference-Cited by-同舟云学术

Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer

Published:2015-12-01 Issue:7 Volume:30 Page:1150-1154
ISSN:0269-3879
Container-title:Biomedical Chromatography
language:en
Short-container-title:Biomed. Chromatogr.

Author:

Hayashi Hideki¹²,Kita Yutaro¹,Iihara Hirotoshi¹²,Yanase Koumei³,Ohno Yasushi³,Hirose Chiemi²,Yamada Maya²,Todoroki Kenichiro⁴,Kitaichi Kiyoyuki⁵,Minatoguchi Shinya³,Itoh Yoshinori²,Sugiyama Tadashi¹

Affiliation:

1. Laboratory of Pharmacy Practice and Social Science; Gifu Pharmaceutical University; Gifu Japan

2. Department of Pharmacy; Gifu University Hospital; Gifu Japan

3. Second Department of Internal Medicine; Gifu University Graduate School of Medicine; Gifu Japan

4. Department of Analytical and Bio-Analytical Chemistry, School of Pharmaceutical Sciences; University of Shizuoka; Shizuoka Japan

5. Laboratory of Pharmaceutics; Gifu Pharmaceutical University; Gifu Japan

Publisher

Wiley

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,General Medicine,Biochemistry,Analytical Chemistry

Reference25 articles.

1. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS;Bouchet;Clinica Chimica Acta,2011

2. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors;Calvo;Journal of Clinical Oncology,2006

3. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry;Chahbouni;Therapeutic Drug Monitoring,2009

4. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours;Eskens;British Journal of Cancer,2008

5. European Medicines Agency Press Release. AstraZeneca withdraws its marketing authorisation application for Zactima (vandetanib) 2009 http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500007024.pdf

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AFATINIB-A COMPREHENSIVE REVIEW OF ANALYTICAL METHODS DEVELOPED IN PHARMACEUTICALS AND BIOLOGICAL MATRICES;International Journal of Applied Pharmaceutics;2024-07-07

2. Simultaneous and Rapid Determination of Plasma Concentrations of Four Tyrosine Kinase Inhibitors Using Liquid Chromatography/Tandem Mass Spectrometry in Patients with Non–Small Cell Lung Cancer;CHROMATOGRAPHY;2023-06-20

3. Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer;Anticancer Research;2023-01-25

4. Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces—A Review;Pharmaceutics;2023-01-10

5. Pharmacokinetics of Afatinib after Intravenous and Oral Administrations in Rats Using Validated UPLC MS/MS Assay;Journal of Chromatographic Science;2023-01-07